Efficacy and Speed of Action of a Product to Control Gastric Hydration and Gastroesophageal Reflux (AQUAA)

Study Off Efficacy and Rapidity of Action of a Product With Sodium Alginate, Calcium and Magnesium Salts, Hyaluronic Acid and Aloe Vera to Control Oesophageal-Gastric Acidity (pH), Symptoms of Gastric Reflux and Hyperacidity

A Randomised, Placebo-Controlled Clinical Trial off the Efficacy and Rapidity of Action of a Product Containing Sodium Alginate, Calcium and Magnesium Salts, Hyaluronic Acid and Aloe Vera to Control Oesophageal-Gastric pH and Reduce Symptoms of Gastric Reflux and Hyperacidity.

Study Overview

• Status: Recruiting
• Conditions: Oesophageal Reflux; Gastric Reflux; Hyperactivity; Stomach
• Intervention / Treatment: Device: Antacid; Other: Control

Detailed Description

The investigators will include patients with gastroesophageal reflux disease and heartburn (more than 3 weekly episodes of heartburn for at least 4 consecutive weeks) not related to medication intake and don't use proton pump blockers or H2-receptor antagonists.

This is a multicentre clinical trial with two-phase design:

Phase I: A double-blind, randomised, placebo-controlled clinical trial to assess the efficacy and rapidity of action of the medical device to reduce clinical symptoms of gastric reflux and hyperacidity under normal conditions of use. This phase I will be performed in primary care clinics.

Phase II: A non-comparative, non-controlled clinical trial to objectively assess, using continuous pH monitoring, the magnitude and rapidity to control gastric and oesophageal pH after taking the product. This phase II will be performed at the Department of Gastroenterology of Medic Center.

The study will begin with the baseline visit (day 0) in which the inclusion and exclusion criteria will be confirmed, the signing of informed consent will be obtained, GERD-Q Questionnaire will be done and treatment will be prescribed, followed by a home recording where patients will record data on episodes of acidity and heartburn occuring during the follow-up week. A face-to-face visit will be at 7 days after to recollect information about total number of daytime and nighttime episodes of acidity/heartburn since the previous visit and repeat the GERD-Q Questionnaire.

• Study Type: Interventional
• Enrollment (Estimated): 50
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Anna Fortuny; Phone Number: +34 938 630 311; Email: anna.fortuny@uriach.com
• Study Contact Backup: Name: Montse Vidal, Ph; Phone Number: +34 663825890; Email: montsevidal@crossdata.es

Study Locations

• Spain
  • Barcelona, Spain, 08008
    • Recruiting
    • Oriol Armengol
    • Contact: Oriol Armengol, Ph; Phone Number: +34 664 362 333

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients of both sexes over 18 years of age
• Patients with gastroesophageal reflux disease and heartburn (more than 3 weekly episodes of heartburn for at least 4 consecutive weeks) not related to medication intake
• Patients not on proton pump blockers or H2-receptor antagonists
• Patients able to understand the study implications and who sign the informed consent.

Exclusion Criteria:

• Pregnant or nursing women
• Patients who are currently using or have used other medications or antacid products for the treatment of reflux and hyperacidity symptoms within 7 days prior to enrolment in this study.
• Patients treated with antihypertensive drugs, calcium channel blockers or non-steroidal anti-inflammatory drugs (NSAIDs)
• Patients with hypercalcaemia, hypertension, renal failure or other conditions in which the use of the components of the investigational product is not recommended.
• Patients with serious diseases that, in the physician's opinion, could interfere with the results of the study or prevent their participation in it.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Intervention (Antacid); An Antacid, a CE marked medical device under normal conditions of use. Sodium alginate (reduces reflux) (250 mg/tablet) Calcium carbonate (reduces acidity) (80 mg/tablet) Magnesium carbonate (reduces acidity) (144 mg/tablet) Hyaluronic acid (mucosal protector) (6.15 mg/tablet) Aloe vera extract without anthraquinones (mucosal protector) (40 mg/tablet) Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day.	Device: Antacid; The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.; Other Names: Aquilea Antacid
Placebo Comparator: Control; The control will consist of a placebo based on excipients without active ingredients that will be formulated so that the tablet has the same appearance as the test product, with three different colour layers. Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day.	Other: Control; The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Intensity of acidity/heartburn	Change in intensity of acidity/heartburn before and after taking the treatment, assessed by the patient using a visual analogue scale (VAS from 0=none to 10=maximum imaginable)	At the beginning and at the end of treatment, an average of 7±1 days in patients
Time from treatment intake to resolution or maximum decrease in acidity/heartburn	Change in time from treatment intake to resolution or maximum decrease in acidity/heartburn as assessed by the patient using a 3-point Likert scale (<1 minute, 1-5 minutes, >5 minutes)	At the beginning and at the end of treatment, an average of 7±1 days in patients
Time elapsed between product intake and intragastric pH > 4	Change in minutes of the time elapsed between product intake and intragastric pH > 4	Baseline visit
Time with intragastric pH > 4 for 20 minutes before and after product intake	Total time in minutes of the time in intragastric pH > 4 for 20 minutes before and after product intake	Baseline visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Demographic data	Sex, ethnicity and age data of patients	Baseline visit
Time of tablet duration in the mouth before complete dissolution	Change in time of tablet duration in the mouth before complete dissolution, assessed using a 4-point Likert scale (< 1 minute, 1-3 minutes, 3-5 min, >5 minutes)	At the beginning and at the end of treatment, an average of 7±1 days in patients
Number of daytime and nightime episodes of acidity/heartburn	Change in number of daytime and nightime episodes of acidity/heartburn (information recorded in the Patient Diary)	An average of 7±1 days in patients
Intensity of reflux before and after treatment	Change in intensity of reflux before and after treatment, assessed by the patient using a visual analogue scale (VAS from 0=none to 10=maximum imaginable)	At the beginning and at the end of treatment, an average of 7±1 days in patients
Gastroesophageal Reflux Disease Questionnaire (GERD-Q) score	Change in Gastroesophageal Reflux Disease Questionnaire (GERD-Q) score. Between 0 and 8 in symptoms questions the score don't mean GERD, more than 8 mean GERD or severe GERD if in impact questions the score is more than 2.	At the beginning and at the end of treatment, an average of 7±1 days in patients
Number of Participants With Adverse Events	Number of Participants With Adverse Events as a Measure of Safety and Tolerability	From the beginning to the end of treatment, an average of 7±1 days in patients
Degree of physician and patient satisfaction with the efficacy, rapidity of action and tolerability of the product	Assessment of degree of physician and patient satisfaction with the efficacy, rapidity of action and tolerability of the product using 5-point Likert scales (0=very dissatisfied, 1=dissatisfied, 2=indifferent, 3=satisfied, 4=very satisfied).	Through study completion, an average of 6 months
Mean intragastric pH	Change in mean intragastric pH for 20 minutes before and after product intake	Baseline visit
Number of episodes of GER (intraoesophageal pH < 4)	Change in the number of episodes of GER (intraoesophageal pH < 4). Evaluation 20 minutes before and after taking the product	Baseline visit
Time with oesophageal pH < 4	Change in the time with oesophageal pH < 4. Evaluation 20 minutes before and after taking the product	Baseline visit
Longest reflux episode (oesophageal pH <4)	Change in the time of longest reflux episode (oesophageal pH <4). Evaluation 20 minutes before and after taking the product	Baseline visit

Collaborators and Investigators

• Sponsor: Uriach Consumer Healthcare
• Investigators: Principal Investigator: Oriol Armengol, Ph, Primary Health Center Poblenou, Barcelona, Spain

Study record dates

Study Major Dates

• Study Start (Actual): September 9, 2021
• Primary Completion (Estimated): May 30, 2023
• Study Completion (Estimated): June 30, 2023

Study Registration Dates

• First Submitted: September 17, 2021
• First Submitted That Met QC Criteria: September 28, 2021
• First Posted (Actual): September 29, 2021

Study Record Updates

• Last Update Posted (Actual): May 26, 2023
• Last Update Submitted That Met QC Criteria: May 24, 2023
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: Gastroenterology; Calcium; Hyaluronic Acid; Aloe Vera; Oesophageal Reflux; Gastric Reflux; Hyperactivity; Stomach; Sodium Alginate; Magnesium Salts
• Additional Relevant MeSH Terms: Digestive System Diseases; Nervous System Diseases; Neurologic Manifestations; Gastrointestinal Diseases; Stomach Diseases; Gastroenteritis; Intestinal Diseases; Dyskinesias; Esophageal Motility Disorders; Deglutition Disorders; Esophageal Diseases; Esophagitis; Peptic Ulcer; Duodenal Diseases; Gastroesophageal Reflux; Esophagitis, Peptic; Hyperkinesis; Molecular Mechanisms of Pharmacological Action; Gastrointestinal Agents; Antacids; Anti-Ulcer Agents
• Other Study ID Numbers: URI-AQUAA-2020-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No